开发一个多刺激响应的磁性纳米凝-水凝纳米复合物,用于延长和控制多克索鲁比释放
Ghasem Rezanejade Bardajee1, Hossein Mahmoodian2,3, Negin Shafiei4
1Department of Polymer and Materials Chemistry, Faculty of Chemistry and Petroleum Sciences, Shahid Beheshti University, Tehran 19839-63113, Iran.
Bioconjugate chemistry
|May 14, 2025
概括
这项研究开发了一种新的磁性纳米凝-水凝纳米复合物,用于控制抗癌药物输送. 该系统提供持续释放和增强的向,显示了改善癌症治疗的希望.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术纳米技术
- 药物输送系统 药物输送系统
背景情况:
- 先进的药物输送系统对瘤学至关重要,需要精确的向和持续的药物释放.
- 目前的系统在实现有效和长时间的治疗剂暴露方面面临着挑战.
研究的目的:
- 合成和表征一个多刺激响应的磁性纳米凝-凝纳米复合材料 (MNHNC) 用于控制和延长抗癌药物递送.
- 评估MNHNC对pH值,温度和磁场对药物释放调节的反应能力.
主要方法:
- 纳入聚N-异烯胺-协烯胺) 纳米凝 (NGs) 进入一个salep-grafted聚烯酸) 水凝矩阵.
- 在现场形成Fe3O4纳米粒子用于磁性响应和交联.
- 多克索鲁比 (DOX) 作为一种模型药物,用于评估释放动力学和体外细胞毒性 (MTT试验).
主要成果:
- MNHNC表现出显著的胀和对pH值,温度和磁场的反应.
- 在某些条件下,DOX的延长释放概况为400小时,由超级案例II运输和零顺序动力学控制.
- 增强机械稳定性,生物相容性 (>95%的细胞活力没有DOX),以及有效的体外抗癌活性.
结论:
- MNHNC表现出强大的机械稳定性,生物相容性和多刺激反应能力.
- 它为瘤学中先进的,有针对性的药物输送系统提供了一个有前途的平台.
- 磁场应用允许微调药物释放率,以改善治疗控制.
相关概念视频
Modified-Release Drug Delivery Systems: Stimuli-Activated
172
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
172
Site-Targeted Drug Delivery Systems: Polymeric Carriers
156
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
156


